After failing to get Seagen Merck turns to Daiichi
In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.
ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
Astra works to avoid a datopotamab double dip
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
Bicycle aims to follow in Padcev’s slipstream
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
ASCO 2023 – Merck’s Kelun deal gets its first validation
Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.
